Hikma Pharmaceuticals Plc (HKMPF) Given Average Rating of “Hold” by Brokerages
Hikma Pharmaceuticals Plc (OTC:HKMPF) has received an average recommendation of “Hold” from the seven research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has issued a buy recommendation on the company.
HKMPF has been the topic of a number of recent analyst reports. ValuEngine upgraded Hikma Pharmaceuticals Plc from a “hold” rating to a “buy” rating in a research note on Thursday, July 27th. Morgan Stanley reiterated an “equal weight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, August 2nd. Jefferies Group LLC upgraded Hikma Pharmaceuticals Plc from an “underperform” rating to a “hold” rating in a research note on Monday, August 21st. Goldman Sachs Group, Inc. (The) lowered Hikma Pharmaceuticals Plc from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 22nd. Finally, Zacks Investment Research upgraded Hikma Pharmaceuticals Plc from a “strong sell” rating to a “hold” rating in a research note on Tuesday.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/04/hikma-pharmaceuticals-plc-hkmpf-given-average-rating-of-hold-by-brokerages.html.
Shares of Hikma Pharmaceuticals Plc (HKMPF) opened at $14.94 on Friday. Hikma Pharmaceuticals Plc has a 52-week low of $14.94 and a 52-week high of $27.50.
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.